

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Degarelix for treating advanced hormone-dependent prostate cancer

Batch 27

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that prostate cancer is more common in older men and African Caribbean men at increased risk compared with white men of the same age in the UK.

Although the UK marketing authorisation is for ‘adult male patients’, it was agreed that the population in the scope should be amended to ‘adults’ because people who have undergone male to female gender reassignment can still develop prostate cancer.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

No evidence was received of differential access to therapy or prognosis in these groups.

It was agreed in the scoping workshop that, should the topic proceed through the appraisal process, access to the technology should not be defined by any of the protected characteristics outlined in the current equalities legislation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft scope were required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified during the scoping process so changes to the matrix were needed.

Approved by Associate Director (name): Helen Knight

Date: 25/07/2013